An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text

Medicine, Endocrinology, Pharmacology +15

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun, Kyle W. Sloop, Corina Loghin et al. · Molecular Metabolism · 2018 · 822 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Brian Finan, Tao Ma, Nickki Ottaway et al. · Science Translational Medicine · 2013 · 675 citations

Medicine, Pharmacokinetics, Pharmacology +16

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Brian Finan, Bin Yang, Nickki Ottaway et al. · Nature Medicine · 2014 · 627 citations · Full text

Life Sciences, Biochemistry, Endocrinology +12

Penetration and enzymatic barriers to peptide and protein absorption

Vincent H.L. Lee, Akira Yamamoto · Advanced Drug Delivery Reviews · 1989 · 408 citations

Pharmacy, Biochemistry, Pharmacokinetics +12